ERBB2 and breast cancer: In the HER2− group, 95 breast cancer patients were discriminated as non-special-type invasive ductal carcinoma (IDO-NOS), 3 breast cancer patients were discriminated as special-type invasive ductal carcinoma (IDO-S), and 5 patients were discriminated as microinvasive carcinoma (MIC).